Added to YB: 2024-09-18
Pitch date: 2024-09-17
SMMT [bullish]
Summit Therapeutics Inc.
-32.86%
current return
Author Info
Company Info
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Market Cap
$13.4B
Pitch Price
$26.17
Price Target
N/A
Dividend
N/A
EV/EBITDA
-14.17
P/E
-14.42
EV/Sales
N/A
Sector
Biotechnology
Category
growth
SMMT: Earthquake in the pharma industry
SMMT: Ivonescimab outperforms Keytruda in Phase III trial for lung cancer. 11mo PFS vs 6mo, 50% ORR vs 39%, 90% DCR vs 71%. $21B valuation, largest pre-revenue biotech. CEO Duggan's track record promising. Insiders bullish w/ $235M private placement. Bispecific antibody targets PD-1 & VEGF. Potential blockbuster, Big Pharma acquisition target.
Read full article (5 min)